Navtemadlin (MDM2 inhibitor)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-10-04 — Navtemadlin Shows Biomarker Response in Patients with R/R Myelofibrosis: Phase 3 POIESIS trial (trial-late) evaluating navtemadlin as add-on to ruxolitinib in JAK inhibitor-naïve MF patients with suboptimal response to Jakafi, alongside reported biomarker responses in R/R MF — advances MDM2 inhibition as a non-JAK add-on pathway from early-phase into late-phase evidence. (novelty: 3)
Open questions
Related
Contributing findings
Navtemadlin Shows Biomarker Response in Patients with R/R Myelofibrosis
04-oct-2026
novelty 3
per-area 3
introduces